Dendreon has announced initiation of another Phase II trial of Provenge® (sipuleucel-T) for the treatment of advanced prostate cancer. According to the company, this multicenter trial, called ProACT (PROstate Active Cellular Therapy), has begun enrolling 120 patients with metastatic, androgen-independent prostate cancer.
Full information about this trial is available on the ClinicalTrials.gov web site, as usual.
All patients will receive active treatment but will be randomized into one of three cohorts which will receive PROVENGE manufactured with different concentrations of the immunizing antigen. Patients will receive three infusions of PROVENGE, each two weeks apart. The trial is being conducted by Dendreon to explore the effect of antigen concentration on CD54 upregulation, a measure of product potency, as well as the immune response. Overall survival data will also be collected.
Filed under: Drugs in development, Management, Treatment Tagged: | cancer, immunotherapy, prostate, Provenge, vaccine
Search for new and
ongoing trials on the
CTAG PCa web site
